Interaction Checker

Pirfenidone interactions

Pirfenidone (Esbriet) has 12 documented interactions across the FDA labels and fact sheets we index: 11 major, 0 moderate, 0 minor, and 1 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Major interactions (11)

  • Cannabidiol (prescription)anticonvulsantMajor

    Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during ESBRIET treatment. (Pirfenidone label, Drug interactions)

  • CarbamazepineanticonvulsantMajor

    Therefore, discontinue use of strong CYP1A2 inducers prior to ESBRIET treatment and avoid the concomitant use of ESBRIET and a strong CYP1A2 inducer [see Clinical Pharmacology (12.3) ] . (Pirfenidone label, Drug interactions)

  • CimetidineH2 blockerMajor

    Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during ESBRIET treatment. (Pirfenidone label, Drug interactions)

  • CiprofloxacinfluoroquinoloneMajor

    If ciprofloxacin at the dosage of 750 mg twice daily cannot be avoided, dosage reductions are recommended [see Dosage and Administration (2.4) ]. (Pirfenidone label, Drug interactions)

  • Deferasiroxiron supplementMajor

    Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during ESBRIET treatment. (Pirfenidone label, Drug interactions)

  • FluvoxamineSSRIMajor

    Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during ESBRIET treatment. (Pirfenidone label, Drug interactions)

  • Lopinavir and ritonavirantiretroviralMajor

    Therefore, discontinue use of strong CYP1A2 inducers prior to ESBRIET treatment and avoid the concomitant use of ESBRIET and a strong CYP1A2 inducer [see Clinical Pharmacology (12.3) ] . (Pirfenidone label, Drug interactions)

  • MexiletineantiarrhythmicMajor

    Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during ESBRIET treatment. (Pirfenidone label, Drug interactions)

  • RitonavirantiretroviralMajor

    Therefore, discontinue use of strong CYP1A2 inducers prior to ESBRIET treatment and avoid the concomitant use of ESBRIET and a strong CYP1A2 inducer [see Clinical Pharmacology (12.3) ] . (Pirfenidone label, Drug interactions)

  • Viloxazinenorepinephrine reuptake inhibitorMajor

    Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during ESBRIET treatment. (Pirfenidone label, Drug interactions)

  • ZileutonCYP1A2 inhibitorMajor

    Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during ESBRIET treatment. (Pirfenidone label, Drug interactions)

No significant interaction reported (1)

  • NintedanibNo interaction

    Pirfenidone In a multiple-dose study conducted to assess the pharmacokinetic effects of concomitant treatment with nintedanib and pirfenidone, the coadministration of nintedanib with pirfenidone did not alter the exposure of either agent [see Clinical Pharmacology (12.3) ] . (Nintedanib label, Drug interactions)

Check Pirfenidone against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.